Niraparib in the Treatment of Previously Treated Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

References

• U.S. Cancer Statistics Working Group . US Cancer Statistics Data Visualizations Tool, based on November 2018 submission data (1999–2016). (2019). www.cdc.gv/cancer/dataviz
   Google Scholar
• Erickson BK , ConnerMG, LandenCNJr. The role of the fallopian tube in the origin of ovarian cancer. Am. J. Obstet. Gynecol.209(5), 409–414 (2013).
   PubMed Web of Science ®Google Scholar
• Boussios S , AbsonC, MoschettaMet al. Poly (ADP-ribose) polymerase inhibitors: talazoparib in ovarian cancer and beyond. Drugs R. D.20(2), 55–73 (2020).
   PubMed Web of Science ®Google Scholar
• FDA label for olaparib (2020). www.azpicentral.com/lynparza_tb/lynparza_tb.pdf#page=1
   Google Scholar
• FDA approval for rubraca. www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf
   Google Scholar
• Karihtala P , MoschettaMet al. Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach. Invest. New Drugs38(1), 181–193 (2020).
   PubMed Web of Science ®Google Scholar
• Gourley C , BalmañaJ, LedermannJAet al. Moving from poly (ADP-ribose) polymerase inhibition to targeting dna repair and dna damage response in cancer therapy. J. Clin. Oncol.37(25), 2257–2269 (2019).
   PubMed Web of Science ®Google Scholar
• Friedberg EC . A brief history of the DNA repair field. Cell Res.18(1), 3–7 (2008).
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA , CeccaldiR, ShapiroGI, D’AndreaAD. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov.5(11), 1137–1154 (2015).
   PubMed Web of Science ®Google Scholar
• Karnak D , EngelkeCG, ParselsLAet al. Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer. Clin. Cancer Res.20(19), 5085–5096 (2014).
   PubMed Web of Science ®Google Scholar
• Patel M , NowsheenS, MaraboyinaS, XiaF. The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review. Cell Biosci.10, 35 (2020).
   PubMed Web of Science ®Google Scholar
• O’Connor MJ . Targeting the DNA damage response in cancer. Mol. Cell.60(4), 547–560 (2015).
   PubMed Web of Science ®Google Scholar
• Lord CJ , AshworthA. The DNA damage response and cancer therapy. Nature481(7381), 287–294 (2012).
   PubMed Web of Science ®Google Scholar
• Lord CJ , AshworthA. BRCAness revisited. Nat. Rev. Cancer.16(2), 110–120 (2016).
   PubMed Web of Science ®Google Scholar
• Jones P , AltamuraS, BoueresJet al. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J. Med. Chem.52(22), 7170–7185 (2009).
   PubMed Web of Science ®Google Scholar
• van Andel L , RosingH, ZhangZet al. Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a (14)C-microtracer and therapeutic dose in cancer patients. Cancer Chemother. Pharmacol.81(1), 39–46 (2018).
   PubMed Web of Science ®Google Scholar
• Sun K , MikuleK, WangZet al. A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models. Oncotarget9(98), 37080–37096 (2018).
   PubMedGoogle Scholar
• Lord CJ , AshworthA. PARP inhibitors: synthetic lethality in the clinic. Science355(6330), 1152–1158 (2017).
   PubMed Web of Science ®Google Scholar
• Sandhu SK , SchelmanWR, WildingGet al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol.14(9), 882–892 (2013).
   PubMed Web of Science ®Google Scholar
• Zhang ZY . Modeling and impact of organ function on the population pharmacokinetics (PK) of niraparib, a selective poly(ADP-ribose) polymerase (PARP)-1 and-2 inhibitor. Ann. Oncol.28 (2017).
   Web of Science ®Google Scholar
• Wang J . The exposure-response relationship of niraparib in patients with gBRCAmut and non-gBRCAmut: results from the ENGOT-OV16/NOVA trial. Ann. Oncol.9, 28 (2017).
   Google Scholar
• Sachdev JC . Safety, pharmacodynamic, and pharmacokinetic profile of TSR-042, an anti-PD-1 monoclonal antibody, in patients (pts) with advanced solid tumors. Ann. Oncol.28, 28 (2017).
   Web of Science ®Google Scholar
• Mirza MR , MonkBJ, HerrstedtJet al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N. Engl. J. Med.375(22), 2154–2164 (2016).
   PubMed Web of Science ®Google Scholar
• Moore KN , SecordAA, GellerMAet al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, Phase II trial. Lancet Oncol.20(5), 636–648 (2019).
   PubMed Web of Science ®Google Scholar
• González-Martín A , PothuriB, VergoteIet al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med.381(25), 2391–2402 (2019).
   PubMed Web of Science ®Google Scholar
• Fabbro M , MooreKN, DørumAet al. Efficacy and safety of niraparib as maintenance treatment in older patients (>/=70 years) with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. Gynecol. Oncol.152(3), 560–567 (2019).
   PubMed Web of Science ®Google Scholar
• FDA label for niraparib. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf
   Google Scholar
• Berek JS , MatulonisUA, PeenUet al. Safety and dose modification for patients receiving niraparib. Ann. Oncol.29(8), 1784–1792 (2018).
   PubMed Web of Science ®Google Scholar
• Oza AM , MatulonisUA, MalanderSet al. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, Phase III, randomised controlled trial. Lancet Oncol.19(8), 1117–1125 (2018).
   PubMed Web of Science ®Google Scholar
• Pilié PG , TangC, MillsGB, YapTA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat. Rev. Clin. Oncol.16(2), 81–104 (2019).
   PubMed Web of Science ®Google Scholar
• Lu Y , ChuA, TurkerMS, GlazerPM. Hypoxia-induced epigenetic regulation and silencing of the BRCA1 promoter. Mol. Cell. Biol.31(16), 3339–3350 (2011).
   PubMed Web of Science ®Google Scholar
• Scanlon SE , GlazerPM. Hypoxic stress facilitates acute activation and chronic downregulation of fanconi anemia proteins. Mol. Cancer Res.12(7), 1016–1028 (2014).
   PubMed Web of Science ®Google Scholar
• Bindra RS , SchafferPJ, MengAet al. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol. Cell. Biol.24(19), 8504–8518 (2004).
   PubMed Web of Science ®Google Scholar
• Wang Z , SunK, XiaoYet al. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. Sci. Rep.9(1), 1853 (2019).
   PubMed Web of Science ®Google Scholar
• Sato H , NiimiA, YasuharaTet al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun.8(1), 1751 (2017).
   PubMed Web of Science ®Google Scholar
• Jiao S , XiaW, YamaguchiHet al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin. Cancer Res.23(14), 3711–3720 (2017).
   PubMed Web of Science ®Google Scholar
• Shen J , ZhaoW, JuZet al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res.79(2), 311–319 (2019).
   PubMed Web of Science ®Google Scholar
• Mirza MR , BirrerMJ, ChristensenRdet al. A Phase I study of bevacizumab in combination with niraparib in patients with platinum-sensitive epithelial ovarian cancer: The ENGOT-OV24/AVANOVA1 trial. J. Clin. Oncol.34, 5555 (2016).
   Web of Science ®Google Scholar
• Mirza MR , Åvall-LundqvistE, BirrerMJet al. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, Phase II, superiority trial. Lancet Oncol.20(10), 1409–1419 (2019).
   PubMed Web of Science ®Google Scholar
• Liu JF , BradyM, MatulonisUAet al. A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer. J. Clin. Oncol.38(Suppl. abstr. 6003), (2020).
   Google Scholar
• Konstantinopoulos PA , WaggonerSE, VidalGAet al. TOPACIO/Keynote-162 (NCT02657889)L a Phase 1/2 study of niraparib+pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC) – Results from ROC cohort. J. Clin. Oncol.36(Suppl. 15), 106 (2018).
   Web of Science ®Google Scholar
• Bitler BG , WatsonZL, WheelerLJ, BehbakhtK. PARP inhibitors: clinical utility and possibilities of overcoming resistance. Gynecol. Oncol.147(3), 695–704 (2017).
   PubMed Web of Science ®Google Scholar
• Lin KK , HarrellMI, OzaAMet al. BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov.9(2), 210–219 (2019).
   PubMed Web of Science ®Google Scholar
• Kondrashova O , ToppM, NesicKet al. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat. Commun.9(1), 3970 (2018).
   PubMedGoogle Scholar
• Moiseeva TN , QianC, SugitaniN, OsmanbeyogluHU, BakkenistCJ. WEE1 kinase inhibitor AZD1775 induces CDK1 kinase-dependent origin firing in unperturbed G1- and S-phase cells. Proc. Natl Acad. Sci. USA116(48), 23891–23893 (2019).
   PubMed Web of Science ®Google Scholar
• Quigley D , AlumkalJJ, WyattAWet al. Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors. Cancer Discov.7(9), 999–1005 (2017).
   PubMed Web of Science ®Google Scholar
• Tapodi A , DebreceniB, HantoKet al. Pivotal role of Akt activation in mitochondrial protection and cell survival by poly(ADP-ribose)polymerase-1 inhibition in oxidative stress. J. Biol. Chem.280(42), 35767–35775 (2005).
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA , BarryWT, BirrerMet al. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion Phase 1b trial. Lancet Oncol.20(4), 570–580 (2019).
   PubMed Web of Science ®Google Scholar